Shots:

• Amgen plans to seek interchangeable status for its adalimumab biosimilar Amjevita. The company plans to launch Amjevita (biosimilar, adalimumab) in 2023 in the US

• Amgen reported that patients are currently being enrolled in P-III studies to support interchangeability designation in the US for biosimilars of Amjevita (adalimumab) and ABP 654 (ustekinumab)
• The company is expected the P-III results shortly for biosimilar Stelara (ustekinumab) to treat PsO and PsA while Eylea (aflibercept) for macular degeneration and Soliris (eculizumab) for PNH and aHUS

Ref: Fierce Pharma | Image: Amgen